Skip to Content
MilliporeSigma
All Photos(1)

Documents

549835

Sigma-Aldrich

2,4,6-Tris(dimethylamino)-1,3,5-triazine

96%

Synonym(s):

Altretamine, Hexamethylmelamine

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C9H18N6
CAS Number:
645-05-6
Molecular Weight:
210.28
EC Number:
211-428-4
MDL number:
MFCD00549245
UNSPSC Code:
12352100
PubChem Substance ID:
24874728
NACRES:
NA.22

assay

96%

mp

171-175 °C (lit.)

SMILES string

CN(C)c1nc(nc(n1)N(C)C)N(C)C

InChI

1S/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H3

InChI key

UUVWYPNAQBNQJQ-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

2,4,6-Tris(dimethylamino)-1,3,5-triazine exhibits antitumor activity.

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Triazines and related products. Part 26. Synthesis and chemistry of bicyclic analogues of the antitumour drug 2, 4, 6-tris (dimethylamino)-1, 3, 5-triazine (hexamethylmelamine).
Langdon SP, et al.
Journal of the Chemical Society. Perkin Transactions 1, 993-998 (1984)
Nina Keldsen et al.
Gynecologic oncology, 88(2), 118-122 (2003-02-15)
To evaluate the activity of oral Altretamine in women with epithelial ovarian carcinoma who responded (PR or CR) to first line chemotherapy but relapsed within 6 months. The protocol was later amended to include patients with relapse within 12 months.
R T Zon et al.
Investigational new drugs, 19(3), 229-231 (2001-09-20)
Thirty patients with advanced renal cell carcinoma were treated on a phase 11 trial with altretamine. Altretamine was administered orally at a dosage of 260 mg/m2 days 1 through 14 with cycles repeated every 28 days. Nausea and vomiting were
Peter Dornan et al.
Chemical communications (Cambridge, England), (31)(31), 3645-3647 (2008-07-31)
A novel method for the cyclotrimerization of dimethylcyanamide to form hexamethylmelamine has been developed using an aluminium amide catalyst; detailed DFT modelling of the catalytic cycle supports a triple insertion, nucleophilic ring closure, deinsertion mechanism.
D S Alberts et al.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 14(2), 224-228 (2004-04-17)
This report provides follow-up progression-free survival (PFS) and median survival data for women who achieved clinical complete remission (cCR) from stage III ovarian cancer after first-line therapy and were treated with altretamine consolidation therapy. Patients who enrolled in the SWOG
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service